158 related articles for article (PubMed ID: 38543061)
1. Head-to-Head Comparison of SSTR Antagonist [
Viswanathan R; Ballal S; Yadav MP; Roesch F; Sheokand P; Satapathy S; Tripathi M; Agarwal S; Moon ES; Bal C
Pharmaceuticals (Basel); 2024 Feb; 17(3):. PubMed ID: 38543061
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
3. [
Kanellopoulos P; Nock BA; Greifenstein L; Baum RP; Roesch F; Maina T
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498918
[TBL] [Abstract][Full Text] [Related]
4. Ga-68 DOTANOC PET/CT imaging in detection of primary site in patients with metastatic neuroendocrine tumours of unknown origin and its impact on clinical decision making: experience from a tertiary care centre in India.
Pruthi A; Pankaj P; Verma R; Jain A; Belho ES; Mahajan H
J Gastrointest Oncol; 2016 Jun; 7(3):449-61. PubMed ID: 27284479
[TBL] [Abstract][Full Text] [Related]
5. Prospective Multicentric Assessment of
Lugat A; Frampas É; Touchefeu Y; Mirallié É; Bras ML; Senellart H; Rauscher A; Fleury V; Campion L; Rohmer V; Couturier OF; Lebtahi R; Rouzet F; Ruszniewski P; Kraeber-Bodéré F; Bourgeois M; Ansquer C
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672462
[TBL] [Abstract][Full Text] [Related]
6. Head-to-Head Comparison of [
Ballal S; Yadav MP; Roesch F; Raju S; Satapathy S; Sheokand P; Moon ES; Martin M; Awarwal S; Tripathi M; Bal C
Thyroid; 2023 Aug; 33(8):974-982. PubMed ID: 37171126
[No Abstract] [Full Text] [Related]
7. Somatostatin receptor expression in lymphomas: a source of false diagnosis of neuroendocrine tumor at
Ruuska T; Ramírez Escalante Y; Vaittinen S; Gardberg M; Kiviniemi A; Marjamäki P; Kemppainen J; Jyrkkiö S; Minn H
Acta Oncol; 2018 Feb; 57(2):283-289. PubMed ID: 28686510
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic values of
Kumar R; Vankadari K; Mittal BR; Bansal D; Trehan A; Sahu JK; Sankhyan N
Eur Radiol; 2021 Jul; 31(7):4587-4594. PubMed ID: 33409780
[TBL] [Abstract][Full Text] [Related]
9. Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors: A Prospective Study in 28 Patients.
Berzaczy D; Giraudo C; Haug AR; Raderer M; Senn D; Karanikas G; Weber M; Mayerhoefer ME
Clin Nucl Med; 2017 Sep; 42(9):669-674. PubMed ID: 28682844
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the safety, biodistribution, dosimetry of [
Liu M; Ren C; Zhang H; Zhang Y; Huang Z; Jia R; Cheng Y; Bai C; Xu Q; Zhu W; Huo L
Eur J Nucl Med Mol Imaging; 2024 Jun; ():. PubMed ID: 38878175
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity Comparison of
Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Contrast-Enhanced CT + CT Enterography and 68Ga-DOTANOC PET/CT in Gastroenteropancreatic Neuroendocrine Tumors.
Sharma A; Das CJ; Makharia GK; Arora G; Kumar R
Clin Nucl Med; 2020 Nov; 45(11):848-853. PubMed ID: 32657875
[TBL] [Abstract][Full Text] [Related]
13. An orthotopic model of pancreatic somatostatin receptor (SSTR)-positive tumors allows bimodal imaging studies using 3T MRI and animal PET-based molecular imaging of SSTR expression.
Stelter L; Amthauer H; Rexin A; Pinkernelle J; Schulz P; Michel R; Denecke T; Stiepani H; Hamm B; Wiedenmann B; Scholz A
Neuroendocrinology; 2008; 87(4):233-42. PubMed ID: 18025811
[TBL] [Abstract][Full Text] [Related]
14. [
Nock BA; Kanellopoulos P; Moon ES; Rouchota M; Loudos G; Ballal S; Yadav MP; Bal C; Mishra P; Sheokand P; Roesch F; Maina T
Pharmaceutics; 2023 Feb; 15(3):. PubMed ID: 36986637
[TBL] [Abstract][Full Text] [Related]
15. A prospective head-to-head comparison of
Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhu Z
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4218-4227. PubMed ID: 35657429
[TBL] [Abstract][Full Text] [Related]
16. Head-to-Head Comparison of
Zhu W; Cheng Y; Wang X; Yao S; Bai C; Zhao H; Jia R; Xu J; Huo L
J Nucl Med; 2020 Jun; 61(6):897-903. PubMed ID: 31676731
[No Abstract] [Full Text] [Related]
17. Role of Ga-68 DOTANOC Positron Emission Tomography/ Computed Tomography Scan in Clinical Management of Patients with Neuroendocrine Tumors and its Correlation with Conventional Imaging- Experience in a Tertiary Care Center in India.
Singh D; Arya A; Agarwal A; Agarwal G; Ravina M; Gambhir S
Indian J Nucl Med; 2022; 37(1):29-36. PubMed ID: 35478677
[TBL] [Abstract][Full Text] [Related]
18. [68Ga]Ga-DOTANOC Uptake at Pancreatic Head/Uncinate Process: Is It a Persistent Diagnostic Pitfall Over Time?
Tabacchi E; Fortunati E; Argalia G; Zanoni L; Calabrò D; Telo S; Campana D; Lamberti G; Ricci C; Casadei R; Fanti S; Ambrosini V
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884602
[TBL] [Abstract][Full Text] [Related]
19. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors.
Ambrosini V; Campana D; Bodei L; Nanni C; Castellucci P; Allegri V; Montini GC; Tomassetti P; Paganelli G; Fanti S
J Nucl Med; 2010 May; 51(5):669-73. PubMed ID: 20395323
[TBL] [Abstract][Full Text] [Related]
20. Comparison of diagnostic efficacy of
Zhang B; He Q; Long Y; Zhang Y; Wang X; Chen Z; Liu J; Zhang X
Front Endocrinol (Lausanne); 2022; 13():962800. PubMed ID: 36213295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
